Huaier

Metadata

Regulatory Status

China (SFDA/NMPA)

• Approved drug: Yes. Huaier Granules (Jinke Huaier Granules) received a New Drug Certificate from the Chinese State Food and Drug Administration (SFDA, now NMPA) in 2002.
• Approved indications: Adjuvant therapy for hepatocellular carcinoma, breast cancer, lung cancer, gastric cancer, colorectal cancer, leukemia, osteosarcoma, malignant lymphoma, and pancreatic cancer. Can be used alone or in combination with other treatments.
• Standard dose: 20 g three times daily (oral granules).
• Traditional use history: Over 1,600 years of documented use in TCM.

United States

• FDA status: Not approved as a drug. Not marketed as a dietary supplement in the US. No GRAS determination.
• Clinical trials: No US-based clinical trials registered as of this writing.

European Union

• Novel food status: Not authorized under EU Novel Food Regulation.
• EMA/HMPC: No assessment report or monograph.

Japan and Korea

• Japan: Not listed in the Japanese Pharmacopoeia. Not commercially available as a health product.
• Korea: Not widely used in Korean traditional medicine; limited commercial availability.

Conditions & Indications

Primary: Hepatocellular Carcinoma Adjuvant Therapy (Strong Evidence)

• Post-surgical adjuvant therapy: The landmark Chen et al. (2018) multicenter Phase III RCT (n=1,002, 39 centers across China) demonstrated that Huaier granule adjuvant therapy after curative resection of HCC (BCLC stages A and B) significantly improved recurrence-free survival compared to the blank control group. The trial represents the highest level of clinical evidence for any medicinal fungus in oncology.
• Post-ablation adjuvant therapy: Multiple prospective cohort studies demonstrate improved recurrence-free survival and overall survival when Huaier granules are administered after thermal ablation of HCC, including in patients within Milan criteria.
• Mechanism in HCC: Huaier proteoglycan enhances anti-tumor immune surveillance (NK cell and CD4+ T cell activation), directly inhibits hepatoma cell proliferation, and sensitizes tumor cells to chemotherapeutic agents such as oxaliplatin via regulation of drug efflux transporters.

Secondary: Breast Cancer Adjuvant Therapy (Moderate Evidence)

• Adjuvant use: A meta-analysis of 27 clinical trials (n=2,562) demonstrated improved quality of life when Huaier granules were combined with conventional breast cancer treatment. Reduced chemotherapy-related myelosuppression and hepatotoxicity were observed. A single-center propensity score matching study demonstrated improved disease-free survival.
• Triple-negative breast cancer: Ongoing Phase III clinical trials are evaluating Huaier granules as adjuvant therapy for high-risk early-stage TNBC.

Secondary: Other Cancers (Preliminary Evidence)

• Lung cancer: In vitro and animal studies demonstrate inhibition of non-small cell lung cancer proliferation via EGFR targeting. Clinical data limited to retrospective studies.
• Colorectal cancer: Preclinical evidence for anti-proliferative and immunomodulatory effects; clinical data emerging but not yet from large RCTs.
• Gastric cancer: Small clinical studies suggest potential benefit as adjuvant therapy; confirmatory trials needed.

Emerging/Preclinical

• Ferroptosis induction: Recent research demonstrates Huaier can simultaneously inhibit the antioxidant pathway SLC7A11/GPX4 while enhancing ferritinophagy, representing a novel dual mechanism for tumor cell death.
• Immune checkpoint synergy: Preclinical studies show Huaier enhances the efficacy of anti-PD-L1 immunotherapy in HCC by remodulating the tumor immune microenvironment.
• Pulmonary vascular remodeling: Early research suggests potential applications beyond oncology, with rodent studies demonstrating mitigation of pulmonary vascular remodeling.

Mechanism of Action

Primary Mechanisms

1. TLR4-NF-kB/MAPK immune activation: The principal bioactive proteoglycan (PS-T/TPG-1, molecular mass ~5.59 x 10^4 Da) activates innate immune cells through Toll-like receptor 4 (TLR4)-dependent signaling. This triggers NF-kB nuclear translocation and MAPK cascade activation in macrophages, promoting production of nitric oxide (NO), TNF-alpha, and IL-6. The immune activation mechanism has been characterized at the molecular level using purified proteoglycan fractions.

2. Adaptive immune enhancement: Huaier upregulates the number and function of CD4+ T cells and natural killer (NK) cells, promotes dendritic cell maturation, and elevates secretion of immunostimulatory cytokines. This enhanced immune surveillance is proposed as the primary mechanism for the observed clinical anti-recurrence effect in HCC.

3. Macrophage polarization: Huaier regulates macrophage polarization from the immunosuppressive M2 phenotype toward the immunostimulatory M1 phenotype within the tumor microenvironment, counteracting tumor-associated immune evasion.

Secondary Mechanisms

• Direct anti-proliferative activity: Huaier extract inhibits tumor cell proliferation through cell cycle arrest, induction of apoptosis (via caspase-3 and mitochondrial pathways), and inhibition of the PI3K/Akt and Wnt/beta-catenin signaling pathways across multiple cancer cell lines.
• Anti-angiogenic effects: Inhibition of VEGF-mediated angiogenesis reduces tumor blood supply and limits metastatic potential.
• Anti-metastatic activity: Suppression of epithelial-mesenchymal transition (EMT) and matrix metalloproteinase (MMP) expression reduces tumor cell migration and invasion.
• Drug efflux modulation: Huaier polysaccharides enhance sensitivity of hepatoma cells to oxaliplatin via downregulation of ABCB1/P-glycoprotein through the miR-224-5p axis.
• Ferroptosis induction: Simultaneous inhibition of the SLC7A11/GPX4 antioxidant pathway and enhancement of ferritinophagy triggers iron-dependent tumor cell death.

Proteoglycan Characterization

The primary active component PS-T (proteoglycan from Trametes) consists of approximately 41% protein and 44% polysaccharide, containing 18 amino acids and 6 monosaccharide types. The polysaccharide fraction includes beta-glucans with immunostimulatory activity. Unlike most medicinal mushroom extracts that rely primarily on polysaccharides, Huaier’s proteoglycan exerts its effects through the coordinated action of both protein and carbohydrate moieties — neither fraction alone fully recapitulates the bioactivity of the intact proteoglycan.

Clinical Evidence Summary

Huaier possesses the strongest clinical trial evidence of any medicinal fungus for an oncological indication, anchored by a multicenter Phase III RCT in hepatocellular carcinoma. However, nearly all clinical data originate from Chinese research institutions.

Hepatocellular Carcinoma

Breast Cancer

Evidence Limitations

• Geographic concentration: Nearly all clinical evidence originates from Chinese institutions. Independent international replication is critically needed to validate findings.
• Open-label design: The landmark Chen et al. (2018) Phase III trial was open-label with a blank (no placebo) control, introducing potential bias in outcome assessment.
• Lack of blinding: Most HCC studies use blank controls rather than placebo, making performance and detection bias a concern.
• Publication bias: The body of evidence is drawn primarily from Chinese-language and Chinese-English oncology journals; negative studies may be underrepresented.
• Heterogeneity in cancer types: While Huaier is approved for multiple cancer types in China, robust Phase III data exist primarily for HCC. Evidence for other cancers relies on smaller studies, retrospective analyses, and meta-analyses of heterogeneous trials.
• Single manufacturer: Virtually all clinical trials use the same commercial product (Jinke Huaier Granules), which limits generalizability to other preparations.

Safety Profile

General Assessment

Huaier granules appear generally well-tolerated in published clinical trials and post-marketing surveillance in China. The Chen et al. (2018) Phase III trial reported 98.5% treatment compliance, suggesting good tolerability. Multiple studies note that Huaier may actually reduce certain chemotherapy-related adverse events (myelosuppression, hepatotoxicity) when used as adjuvant therapy. Long-term safety data from controlled trials extend to approximately 96 weeks.

Contraindications

• Pregnancy and lactation: Contraindicated. Pregnant and lactating women are excluded from all clinical trial protocols. No human safety data in pregnancy.
• Autoimmune disease: Theoretical concern that TLR4-mediated immune activation could exacerbate autoimmune conditions. No clinical data to confirm or refute this risk.
• Organ transplant recipients: Immunostimulatory effects could theoretically counteract immunosuppressive therapy. Avoid concurrent use without physician oversight.

Drug Interactions

• Immunosuppressants (cyclosporine, tacrolimus, mycophenolate): Huaier’s potent immune-activating properties may antagonize immunosuppressive therapy. Contraindicated in transplant recipients.
• Chemotherapeutic agents: Huaier appears to enhance sensitivity to oxaliplatin and may have additive effects with other chemotherapy agents. While this may be therapeutically desirable under oncologist supervision, it also raises the possibility of enhanced toxicity.
• Immune checkpoint inhibitors (anti-PD-1, anti-PD-L1): Preclinical evidence suggests Huaier may enhance efficacy of immunotherapy. Clinical implications of this interaction are under active investigation.
• Anticoagulants: No specific data on anticoagulant interactions. As a precaution, monitor patients on concurrent anticoagulant therapy.

Side Effects (at Recommended Doses)

• Common: Generally well-tolerated. Mild gastrointestinal discomfort (nausea, diarrhea, abdominal distension) reported infrequently.
• Uncommon: Mild and transient elevations in liver enzymes reported in some studies, though incidence was not significantly different from control groups.
• Rare: Allergic reactions in individuals with fungal sensitivities.

Toxicology

• Acute toxicity: Preclinical studies in animal models demonstrate negligible toxicity to healthy cells and organs at therapeutic doses.
• Chronic toxicity: No significant organ toxicity observed in animal studies at doses well above the clinical equivalent.
• Quality concerns: As a pharmaceutical product manufactured under GMP in China (rather than a supplement), Huaier granules have more consistent quality control than most medicinal mushroom products. However, products obtained outside official Chinese pharmaceutical channels may not meet the same standards.

Clinical Dosage

Huaier Granules (Approved Pharmaceutical Product)

• Standard dose: 20 g three times daily (60 g total daily), dissolved in warm water, taken orally
• This is the dose used in the Phase III HCC trial and most published clinical studies
• Composition: Aqueous extract of Trametes robiniophila combined with sucrose, dextrin, and soluble starch in a 2:2:1 ratio
• Duration: Typically administered for 48—96 weeks in adjuvant oncology protocols; long-term maintenance use is common in Chinese clinical practice
• Manufacturer: Qidong Gaitianli Pharmaceutical Co., Ltd., Jiangsu Province, China

Lower Dose Protocol

• Alternate dose: 10 g three times daily (30 g total daily) used in some breast cancer clinical trials
• May be appropriate for patients with gastrointestinal sensitivity or as an initial dose before escalation

Aqueous Extract (Research Setting)

• Experimental concentrations: 1—6 mg/mL used in in vitro studies
• Not standardized for clinical use outside the approved granule formulation

Important Notes on Access

Huaier granules are a regulated pharmaceutical product in China and are not commercially available as dietary supplements in the US, EU, or Japan. Patients seeking this therapy should do so under the supervision of an oncologist familiar with the product. Self-medication with unverified Huaier products obtained through unofficial channels is not recommended.

Sources

• Chen Q, Shu C, Laurence AD, et al. Effect of Huaier granule on recurrence after curative resection of HCC: a multicentre, randomised clinical trial. Gut. 2018;67(11):2006-2016
• Yang F, Fan L, Zhu T, et al. An immune-stimulating proteoglycan from the medicinal mushroom Huaier up-regulates NF-kB and MAPK signaling via Toll-like receptor 4. J Biol Chem. 2019;294(7):2628-2641
• Song X, Li Y, Zhang H, Yang Q. The anticancer effect of Huaier (Review). Oncol Rep. 2015;34(1):12-21
• Zhang N, Kong X, Yan S, Yuan C, Yang Q. Huaier aqueous extract inhibits proliferation of breast cancer cells by inducing apoptosis. Cancer Sci. 2010;101(11):2375-2383
• Wang X, Zhang N, Huo Q, Yang Q. Anti-angiogenic and antitumor activities of Huaier aqueous extract. Oncol Rep. 2012;28(4):1167-1175
• Yan X, Lyu T, Jia N, Yu Y, Hua K, Feng W. Trametes robiniophila Murr: a traditional Chinese medicine with potent anti-tumor effects. Cancer Manag Res. 2019;11:1541-1549
• Chen J, Chen S, Zhou Y, Wang S, Wu W. Efficacy and safety of Huaier granule as an adjuvant therapy for cancer: an overview of systematic reviews and meta-analyses. Integr Cancer Ther. 2022;21:15347354221083910
• Liu X, Wang Z, Zhao Y, et al. Huaier granule prolongs overall survival after curative resection of hepatocarcinoma carcinoma: a propensity score analysis. Phytomedicine. 2022;106:154435
• Li Z, Chen S, Fan Y, et al. Long-term oral administration of Huaier granules improves survival outcomes in hepatocellular carcinoma patients within Milan criteria following microwave ablation. Front Pharmacol. 2024;15:1336347
• Zhu L, Li J, Ye J, et al. Traditional Chinese biomedical preparation (Huaier Granule) for breast cancer: a PRISMA-compliant meta-analysis. Biosci Rep. 2020;40(8):BSR20202509
• Chinese State Food and Drug Administration. New Drug Certificate for Huaier Granules. 2002

Connections

• Polypore immunomodulators: Huaier belongs to the same family (Polyporaceae) as Turkey Tail (Trametes versicolor), which similarly employs polysaccharide-protein complexes (PSK, PSP) for immune modulation in oncology. Turkey Tail PSK is approved as an adjuvant cancer therapy in Japan, paralleling Huaier’s approval in China. Together they represent the two most clinically validated medicinal fungi in oncology worldwide.
• Hepatoprotective fungi: Compare with Reishi (Ganoderma lucidum), which is also used adjunctively in Chinese oncology and shares hepatoprotective and immunomodulatory properties, though with weaker clinical trial evidence for specific oncological endpoints.
• Tumor-associated immune modulation: The TLR4-dependent mechanism of Huaier proteoglycan parallels the dectin-1 and TLR-2 mediated immune activation seen with beta-glucans from Maitake (D-fraction) and Phellinus linteus. However, Huaier’s proteoglycan is pharmacologically distinct in that both protein and polysaccharide moieties are required for full activity.
• Sanghuang comparison: Sanghuangporus sanghuang is another Chinese medicinal polypore with anti-cancer research, though it lacks the Phase III clinical trial data that distinguishes Huaier.
• Clinical evidence hierarchy: Among all medicinal fungi, Huaier possesses arguably the strongest single clinical trial (Phase III, n=1,002) for any specific therapeutic indication, though the open-label design and geographic concentration of evidence are notable limitations.